
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2008

THE COOPER COMPANIES, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

1-8597
(Commission File Number)

94-2657368
(IRS Employer
Identification No.)

6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588
(Address of principal executive offices)

(925) 460-3600
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 7.01. Regulation FD Disclosure.

On September 18, 2008, The Cooper Companies, Inc. will host an Analyst Meeting. A copy of that presentation is furnished as Exhibit 99.1 to this Current Report and shall not be deemed "filed" under the Securities Exchange Act of 1934, as amended.

Internet addresses in the release are for information purposes only and are not intended to be hyperlinks to other The Cooper Companies, Inc. information.

ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Analyst presentation dated September 18, 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE COOPER COMPANIES, INC.

By /s/ Rodney E. Folden
Rodney E. Folden
Corporate Controller
(Principal Accounting Officer)

Dated: September 17, 2008

EXHIBIT INDEX

Exhibit No.

Description

99.1

Analyst presentation dated September 18, 2008.



Analyst Meeting 2008

September 18, 2008





Opening Remarks and Management Introductions

AI White

**Vice President, Investor Relations and
Treasurer**

Agenda

7:30 am	Registration	
8:30 am	Welcome and Introductions	Al White
8:35 am	Strategic Overview	Bob Weiss
9:15 am	CVI Business Unit	John Weber
	CVI Commercial Update	Jeff McLean
	CVI Manufacturing	Fernando Torre
	CVI R&D	Arthur Back
10:15 am	Break	
10:30 am	CSI Business Unit	Nick Pichotta
11:00 am	Finance Review and Outlook	Gene Midlock
11:15 am	Summary	Bob Weiss
	Question and Answer Session	

Forward Looking Statements

This presentation contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including projections of Cooper's results. To identify these statements look for words like "targets," "expects," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Actual results could differ materially from the projections made in this presentation. Additional information concerning factors that could cause material differences can be found in Cooper's periodic filings with the Securities and Exchange Commission. They are available publicly and on request from Cooper's investor relations department.



Strategic Overview

Bob Weiss
President & Chief Executive Officer

One Year in the Saddle

➤ Year 1 Accomplishments:

- Concluded integration and restructuring
- Addressed new product capacity constraints
- Launched key new product -- Avaira
- Strengthened management team
- Completed capital expansion program

3-5 Year Plan

- Driving Revenue
 - Recession resistant
 - Market share gains
 - Geographic expansion
 - Rollout of best in class products in each modality
 - PC 1 Day – Single use 34% WW market
 - Avaira – 2 week 39% WW market
 - Biofinity – Monthly and beyond 27% of WW market
 - Materials
 - Third generation SiH 30% WW market
 - ProClear family – Best-in-class conventional hydrogels 70% WW market
 - New Product Rollouts
 - Biofinity (SiH) monthly toric Calendar 1Q09
 - PC 1 Day – Japan Fiscal 1H09
 - Avaira (SiH) 2 week toric Calendar 4Q09
 - SiH Multifocal Fiscal 2010
 - 3-5 Year Target – 1.5x Market

3-5 Year Plan

- Driving Gross Margin
 - Leverage manufacturing platform
 - Conversion onto GenII completed
 - Leverage Biofinity production lines into Specialty Lenses and Avaira
 - Improve GenII footprint and efficiency
 - Leverage material platform
 - SiH materials to Specialty Lenses
 - Significant cost reductions in using PC material
 - Significant cost reductions in using SiH materials
 - 3-5 Year Target – Low 60s

3-5 Year Plan

▪ Leveraging Operating Expense

– SG&A

- Sales & Marketing growing with revenues to support product launches
- Distribution consolidation completed
- General & Administrative leverage

– R&D

- Grow with revenues

– 3-5 Year Target -

- Grow OpEx at 70-90% of Revenue growth rate
- Leverage OpEx from mid-40's to low 40's as a % of Revenue

3-5 Year Plan

- Driving Earnings Growth
 - Maintain low effective tax rate
 - Reduce interest expense
 - 3-5 Year Target – Exceed 15% EPS growth

3-5 Year Plan

- Generating Solid Cash Flow
 - Lower CapEx requirements
 - FY2009: \$125-140M
 - FY2010 onward: sub-\$125M
 - Improve inventory months-on-hand (MOH)
 - Distribution consolidation completed
 - New systems (Logility)
 - 3-5 Year Target -
 - \$1B+ of Operating Cash Flow '09-12
 - Over 50% will be Free Cash Flow

3-5 Year Plan

- Deleveraging Balance Sheet
 - Lower MoH
 - Lower CapEx
 - Strong FCF
 - 3-5 Year Target –
 - Debt/Cap under 30%
 - FD/EBITDA under 3x

5 Key Takeaways for Today

- Depth of management team
- Well positioned to leverage growth
- Market leading product lines
- Integration completed
- Driving efficiencies



CooperVision Business Unit

John Weber
President

CooperVision – Overview

- Global manufacturer of contact lenses
 - Approx. 7,000 employees in more than 54 countries
 - YTD 2008 growth has outpaced the market
- Since 2005:
 - Reduced and strategically focused distribution centers
 - Expanded product portfolio and introduced two world class silicone spheres
 - Leveraged manufacturing technology around the world
 - Increased R&D investment to 1.7x 2005 levels
- Product mix: 42% Specialty, 39% Spherical, 19% Single Use
- Geographic mix: 44% Americas, 39% Europe, 17% Asia-Pacific


CooperVision's Global Segments

Americas

% of CVI Sales: 44%
Market Position: #2
Led By: J. McLean
Strategic Focus: Share Growth

Asia-Pac

% of CVI Sales: 17%
Market Position: #4
Led By: Dr. J.C. Aragon
Strategic Focus: Investment



EMEA

% of CVI Sales: 39%
Market Position: #2
Led By: A. Sedgwick
Strategic Focus: Expansion Growth

CooperVision's Goals

- CooperVision targets growing revenue 1.5X the contact lens market and leveraging our expenses to drive bottom line profitability and free cash flow

- Targeted Strategy Components:
 - Best in class products competing in all major modalities and materials
 - Flexible market strategy offering a clear alternative to the market leader
 - Expanding presence in the Asia Pacific region
 - Operational excellence supporting flexibility in an efficient manner

The CooperVision Management Team

- CooperVision has assembled a strong management team, capable of delivering improved bottom line financial results through revenue growth and leveraging expenses
- The team has the skills, experience, and expertise in all key functions required to successfully lead and manage a contact lens company
- Three key members of the executive management team presenting today

Jeff McLean

- Executive Vice-President, Commercial Strategy
- Promoted in April 2008 from CooperVision's President of the Americas
- Responsibilities include:
 - Developing and coordinating commercial strategy
 - Company positioning
 - Product positioning
 - Interacting with R&D to determine and monitor product development strategy
- Background includes several successful management sales & marketing positions over 27 years within the contact lens industry

Fernando Torre

- Vice-President, Manufacturing
- Responsibilities include
 - Improving and maintaining high standard of lens quality
 - Manufacturing scale up of silicone hydrogel capacity
 - Continuously driving down COGS
- Background includes progressive engineering and manufacturing management positions
 - Over seven years experience leading high-volume contact lens manufacturing plants at CooperVision
 - Began career as an R&D engineer and project manager, which allowed leveraging our technology transfer process – positive results demonstrated in Avaira and silicone hydrogel toric capacity expansions

Dr. Arthur Back

- Vice-President, Research and Development
- Responsibilities include
 - Developing CVI's family of silicone hydrogel products, including currently transferring silicone hydrogel torics to manufacturing plants
 - Continuously improving product performance
 - Developing and executing product pipeline
- Background includes a successful career in contact lens optics and materials research
 - PhD with 24 years experience of contact lens research and development
 - Successfully managed the Avaira technology transfer to our manufacturing plants



CooperVision Commercial Update

Jeff McLean
Executive Vice President,
Commercial Strategy

Our Vision

To Enhance Each and
Every Contact Lens Experience



Our Mission

We market contact lenses that enhance the experience of eye care providers and wearers alike through the application of technology, expertise and service. We listen to our customers and respond to their diverse needs.




CooperVision®




Market Trends

U.S. Silicone as a % of Total Market Since Intro on TP Basis




Source: Independent Market Research Data/Management Estimates

U.S. % of Total Worldwide Silicone Patients




Source: Independent Market Research Data/Management Estimates

Competitive Shares of Total Silicone Lenses on a TP Basis




Source: Independent Market Research Data/Management Estimates

Competitive Shares of Silicone Spheres On a TP Basis




Source: Independent Market Research Data/Management Estimates

Soft Patient Visits - Last 8 Period Trend




Source: Independent Market Research Data/Management Estimates

Total Patient Share Total Soft Lenses – HPR




Source: Health Product Research (HPR)

NF/RF Patient Share Total Soft Lenses – HPR



Source: Health Product Research (HPR)

Easy To Do Business With



	Wave 1	Wave 2	Wave 3	Wave 4	Wave 5
■ Ciba	8.14	8.34	8.09	8.22	8.20
■ Johnson & Johnson	7.82	7.88	7.97	8.32	8.25
■ CooperVision	8.04	8.26	8.32	8.40	8.32
■ Bausch & Lomb	7.89	7.97	7.59	7.57	7.59
■ mean importance	8.83	8.83	8.83	8.83	8.83

[Wave 5 N = 323]

Source: Independent Market Research Data/Management Estimates

2→2→1→1→1

Global Market Statistics

Modality Breakdown

Americas

Daily: 10%
2-Week: 65%
Monthly: 25%

EMEA

Daily: 38%
2-Week: 12%
Monthly: 50%

Asia-Pac

Daily: 57%
2-Week: 28%
Monthly: 15%

Global


Daily: 34%
2-Week: 39%
Monthly: 27%

**CooperVision's Opportunity is Tremendous –
We Compete In All Segments**

Source: Management estimates

CVI - Keys To Success

- We win:
 - On intangibles
 - Culture
 - Flexibility
 - Approachability
 - Team
 - On focus – we market contact lenses
 - On flexibility – private label
 - And we continually challenge ourselves to be different
- We tie:
 - On product portfolio
 - R&D Pipeline
 - Manufacturing Technology
- We lose:
 - Consumer awareness






CooperVision Manufacturing

Fernando Torre
Vice President, Manufacturing


Global Manufacturing Organization




Global Manufacturing Organization




Manufacturing Volume by Plant




Manufacturing Capacity Trend



Manufacturing Productivity Trend



Manufacturing Ramp up for Avaira vs. Biofinity



Note: Volume estimates are based on actual and forecasted production.



CooperVision Research & Development


Arthur Back
BOptom PhD FAAO
Vice President, R&D

	Pre-2005	2008
Sites	Southampton, UK	Southampton, UK Pleasanton, CA
Square Footage	10,000	44,000
Employees	30	115
PhD Level Scientists	2	30
Prototype Manufacturing Lines	1	5
Material Competency	80% external	20% external
Annual Investment (CVI)	sub-\$10M	Approx. \$32.5M

- Proclear 1 Day
- Biomedics EP in Omafilcon A
- Evolution 1 Day (Japan)
- Single use Ocufilcon D toric
- Biofinity monthly silicone hydrogel
- Avaira 2 week silicone hydrogel



- Advanced Contact Lens Materials
 - Advanced Hydrogels
 - Advanced Silicones
 - Value-Added Materials
- Advanced Designs in Specialty Category
 - Vision Correction



- Multiple new products anticipated through to 2010
 - Key specialty products into silicone materials
 - New materials
 - Other design/chemistry
- Continue focus on developing internal R&D function



CooperSurgical Business Unit Update

Nick Pichotta
CEO

CooperSurgical - Overview

CooperSurgical (CSI) develops, manufactures, and markets medical devices, diagnostic products and surgical instruments for gynecologists and obstetricians


- Leader of the fragmented US medical device segment of women's healthcare
 - Holds an estimated 9% share of \$1.6M market*
- Leader of in-office OB/GYN products
- Headquartered in Trumbull, CT

Management team

- *Nicholas J. Pichotta, CEO*
- *Paul L. Remmell, President & COO*
- *Robert D. Auerbach, M.D., FACOG, SVP & Chief Medical Officer*


Total Employees	555
G&A	43
Sales, Marketing	127
Cust Service, Tech Support	29
Engineering	14
Manufacturing	322
Distribution	20

Revenues by Point of Sale



History of CooperSurgical

- CSI was founded as a start up subsidiary within COO in 1990
- Top line growth every year since 1996
- Proven track record of successful M&A execution and integration
 - Completed 23 acquisitions in the past 10 years
 - Strong focus on increasing margins through management expertise and superior manufacturing/distribution capabilities



Women's Healthcare Market

➤ Demographic trends through 2025:

- Number of women of reproductive age will grow by 10%
- Women between the ages of 45 and 64 will grow by 30%

➤ Impact on visit activity:

- Birth-related visits stable
- Fertility visits increase
- Hysterectomy rates stable
- Incontinence visits and surgical procedures increase
- Sterilization rates stable
- Management of menopausal symptoms increase

Why Women Visit an OB/GYN*	2006 Visits (000)
Normal Pregnancy	22,066
Gynecologic Examination	20,175
Contraceptive Management	14,396
Female Climacteric (menopause)	6,607
Menstrual Disorders	6,053
Vaginitis	5,701
Osteoporosis	4,043
Surgery follow-up	3,150
Abnormal Pap Smears	3,028
Routine Post-partum follow-up	2,974
Urinary tract infection	2,643
Genital symptoms	2,065
Absence of menstruation	1,061
Infertility screening	936
Incontinence of urine	613
Other	40,866
Total	136,377

Source: Independent Market Research Data/Management Estimates

*Source: Verispan PDDA, 2006 top 50 Diagnosis

Key U.S. Hospital Procedures

Procedure Type	# of Procedures (000)
Childbirth	4,100
Pelvic floor surgery	192
Operations on female genital organs	4,058
Oophorectomy and salpingo-oophorectomy	511
Bilateral destruction or occlusion of fallopian tube	662
Hysteroscopy	237
Excision or destruction of lesion or tissue of uterus and supporting structures	179
Abdominal hysterectomy and hysterectomy not otherwise specified	407
Vaginal hysterectomy	184
Diagnostic dilation and curettage	475

Source: Independent Market Research Data/Management Estimates


Women's Healthcare Points of Care

Provider breakdown

- OB/GYN Offices 13,665
- Hospitals 4,290
- Fertility Clinics 394


➤ Group Practice Profiles:

Type of Group	Number of Practices	Number of OB/GYNs
Single Specialty	11,177	26,595
Multi-specialty	2,488	5,738
Total	13,665	32,333




Source: Independent Market Research Data/Management Estimates

CSI Sales Force



CSI Product Lines by Point of Care




Hospital/OR	Competitors	Market Share
Surgical Sterilization	5	15%
Uterine Manipulation	5	50%
Trocar Closure Device	2	70%
Surgical Site Retractor	3	60%
Neonatal Products	4	20%
Vacuum Assisted Delivery	1	30%
Hysterosonography Device	4	40%

IVF	Competitors	Market Share
IVF Product	7	30%

Office	Competitors	Market Share
Incontinence	3	60%
Colposcopy	4	70%
Gyn Office Instruments	10	10%
Pap Brush	2	90%
Fetal Dopplers & Monitors	5	5%
LEEP Products	10	40%
Endometrial Sampler	7	70%

Current Product Portfolio: Office

HPV Management



Uterine Conditions Management



Incontinence



Obstetrics



Gynecologic Instruments and Disposables



Osteoporosis



Current Product Portfolio: Hospital

Uterine Conditions Management



Sterilization



Obstetrics



Surgical Site Management



Green Surgical Trocars



Port Site Closure



Current Product Portfolio: Assisted Reproductive Technologies



CSI Performance

➤ Revenue details:

- 15% CAGR from 2005 through 2008E
- 15% of revenues are international
- 19 core product categories with over 600 products


➤ Margin Details

- Consistent GPM and OM improvements over the past several years


➤ Other

- Minimal CapEx requirements
- Significant Free Cash Flow generation

CSI Revenue & Operating Margin*



CSI Quarterly Revenue & Operating Margin*



Strategies for Growth

- Focus on women's health
- Continue to consolidate the market
- Advance technologies
- Grow hospital and fertility segments
- Capitalize on demographic trends

Key Takeaways

- Well established/recognized manufacturer of OB/GYN devices
- Dedicated to provide the highest quality of products and service to the OB/GYN
- Highly skilled direct sales force to cover the US office and outpatient hospital markets
- Strong sales presence in GYN OR, L&D and Fertility Clinics enhances the relationship with the OB/GYN
- Strong pipeline including a new Trocar product



Financial Review & Outlook

Gene Midlock
Chief Financial Officer

Six Months – Areas of Focus

- Six Months Areas of Focus:
 - Free Cash Flow
 - Debt Reduction
 - Enhanced Forecasting
 - Reduction and Leveraging of G&A

Q4 and 2009 Guidance

➤ Fiscal 4Q08 Guidance*

- EPS: \$0.58-\$0.64
- Revenue: \$285M - \$295M
- Gross Margin: Approx. 60%
- FCF: Positive
- ETR: 26.5%
- Share Count: 45.3M
- No Callouts anticipated

➤ Fiscal 2009*

- CapEx: \$125-\$140M
- ETR: 15-17%
- No Callouts anticipated
- Additional Guidance on 4Q Earnings Call (Dec. 9)

* As issued on 9/4/08.

Effective Tax Rate

- Annual rate
 - Fairly consistent – 2008 15 – 17%
 - Geographic mix
 - Risk reserve – favorable audit history is decreasing reserves
- Quarterly rate volatility – Risk reserve for uncertainties
 - GAAP requirement as “discrete items”
 - release of reserves in quarter in which statute of limitations expires, or probability of assessment changes
 - Setting up of interest reserves on a quarterly basis
 - Operations in 25 countries, with differing tax laws
- FY 2008 “discrete items” by quarter
 - Q1, \$500k. Q2, \$200k. Q3, (\$4.9M) Q4, \$100k
- FY 2009 anticipated “discrete items” by quarter
 - Q1 and Q4, relatively large; Q2 none; Q3, moderate

Gross Margin Drivers

- Product mix
 - driven by single-use, SiH and specialty lenses
- Leveraging manufacturing capability
 - Gen II conversion
- FX
 - Off-shore sales and manufacturing
 - Hedging
 - Off-shore inventory

Foreign Exchange

- Currency Hedges impacted Gross Margins 290 bps in Q3 (non-GAAP)
 - All contacts designated against COGS

	Non-GAAP (USD) Scenarios Comparison	
	Q3 (No Hedges)	Q3 (COGS)
Revenue	285,884,000	285,884,000
COGS	113,520,753	121,899,000
Total Q3	172,363,247	163,985,000
Gross Margin	60.3%	57.4%
GM Difference	-	2.9%

Operating Margin Drivers

- Sales & Marketing
 - Support new product launches
- Distribution
 - Distribution center consolidation
- R&D
 - Growing with sales
- G&A



In Summary

5 Key Takeaways

- Depth of management team
- Well positioned to leverage growth
- Market leading product lines
- Integration completed
- Driving efficiencies



QUESTIONS?

Contacts:

- Robert S. Weiss
President and Chief Executive Officer

- Eugene J. Midlock
Senior Vice President and Chief Financial Officer

- Albert G. White III
Vice President, Investor Relations & Treasurer
Phone: 925-460-3663
Fax: 925-460-3648
Email: awhite@cooperco.com

- Kim Duncan
Director, Investor Relations
Phone: 925-460-3663
Fax: 925-460-3648
Email: kduncan@cooperco.com

Corporate Headquarters:

6140 Stoneridge Mall Road, Ste 590
Pleasanton, CA 94588

www.cooperco.com

www.coopervision.com

www.coopersurgical.com